恒瑞医药(600276.SH)：HRS-6257片获批开展用于术后镇痛的临床试验

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS-6257 tablets, aimed at treating acute and chronic pain, with no similar drugs approved in the domestic market [1] Group 1 - The company’s subsidiary, Shanghai Heng Rui Medicine Co., Ltd., has been granted a clinical trial approval notice for HRS-6257 tablets [1] - The clinical trials for HRS-6257 are set to commence shortly [1] - HRS-6257 is intended for the treatment of both acute and chronic pain [1] Group 2 - Currently, there are no approved drugs targeting the same mechanism in the domestic market [1]